Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
MedPacto Inc banner
M

MedPacto Inc
KOSDAQ:235980

Watchlist Manager
MedPacto Inc
KOSDAQ:235980
Watchlist
Price: 5 750 KRW -4.96% Market Closed
Market Cap: ₩197.1B
Write Note Create Alert Ask AI

Gross Margin

8.9%
Current
Improving
by 7.5%
vs 3-y average of 1.4%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
8.9%
=
Gross Profit
₩220.1m
/
Revenue
₩2.5B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
8.9%
=
Gross Profit
₩220.1m
/
Revenue
₩2.5B

Peer Comparison

Country Company Market Cap Gross
Margin
KR
MedPacto Inc
KOSDAQ:235980
197.1B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
399.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
202.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
188.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
74.2B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 82% of companies in Korea
Percentile
18th
Based on 2 511 companies
18th percentile
8.9%
Low
-646.5% — 12.8%
Typical Range
12.8% — 32.2%
High
32.2% — 54 001.3%
Distribution Statistics
Korea
Min -646.5%
30th Percentile 12.8%
Median 19.7%
70th Percentile 32.2%
Max 54 001.3%

Other Profitability Ratios

MedPacto Inc
Glance View

Market Cap
197.1B KRW
Industry
Biotechnology

MedPacto, Inc. researches and develops anti-cancer drugs. The company is headquartered in Seoul, Seoul. The company went IPO on 2019-12-19. The firm researches and develops anticancer drugs and diagnostic kits including vactosertib, MA-B2 and others. The products are used as the treatment of multiple myeloma, lung cancer, stomach cancer, colon cancer, blood cancer, triple negative breast cancer and pancreatic cancer, among others.

Intrinsic Value
1 049.36 KRW
Overvaluation 82%
Intrinsic Value
Price
M
What is Intrinsic Value?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
8.9%
=
Gross Profit
₩220.1m
/
Revenue
₩2.5B
What is MedPacto Inc's current Gross Margin?

The current Gross Margin for MedPacto Inc is 8.9%, which is above its 3-year median of 1.4%.

How has Gross Margin changed over time?

Over the last 6 months, MedPacto Inc’s Gross Margin has increased from -13.9% to 8.9%. During this period, it reached a low of -13.9% on Mar 31, 2025 and a high of 9.3% on Jun 30, 2025.

Back to Top
ALPHA SPREAD
Follow us
Join more than 319,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.